{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T02:19:06Z","timestamp":1782785946892,"version":"3.54.5"},"reference-count":39,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2013,2,22]],"date-time":"2013-02-22T00:00:00Z","timestamp":1361491200000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2013,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:label\/><jats:p>Allopurinol, one of the most commonly used uric acid\u2013lowering agents, can cause serious adverse events. To investigate the risk factors for allopurinol\u2010induced adverse events, the authors enrolled 94 patients who developed allopurinol\u2010induced adverse events and 378 controls who were randomly chosen from 1934 patients who used allopurinol but did not develop any adverse events in this retrospective case control study. Univariate analysis showed that patients who developed allopurinol\u2010induced adverse events had more chronic kidney disease (46% vs 30%, <jats:italic>P<\/jats:italic> = .005), more hypertension (42% vs 30%, <jats:italic>P<\/jats:italic> = .036), less tumor lysis syndrome (<jats:italic>P<\/jats:italic> = .030), higher cholesterol (<jats:italic>P<\/jats:italic> = .013), and lower aspartate aminotransferase (<jats:italic>P<\/jats:italic> = .002) and alanine aminotransferase levels (<jats:italic>P<\/jats:italic> = .033) and more commonly used angiotensin receptor blockers (27% vs 15%, <jats:italic>P<\/jats:italic> = .007), colchicines (16% vs 5%, <jats:italic>P<\/jats:italic> = .010), or statins (19% vs 8%, <jats:italic>P<\/jats:italic> = .002) than those who did not. In multiple logistic regression analysis, the use of colchicines (odds ratio, 3.11; 95% confidence interval, 1.28\u20107.58; <jats:italic>P<\/jats:italic> = .012) and statins (2.10; 1.03\u20104.25; <jats:italic>P<\/jats:italic> = .041) was an independent risk factor predicting adverse events in allopurinol users. In conclusion, patients who use colchicine or statins are at significant risk for developing allopurinol\u2010induced adverse events.<\/jats:p><\/jats:sec>","DOI":"10.1177\/0091270012439715","type":"journal-article","created":{"date-parts":[[2012,3,16]],"date-time":"2012-03-16T05:06:38Z","timestamp":1331874398000},"page":"211-216","source":"Crossref","is-referenced-by-count":32,"title":["Clinical Risk Factors for Adverse Events in Allopurinol Users"],"prefix":"10.1002","volume":"53","author":[{"given":"Hee Jung","family":"Ryu","sequence":"first","affiliation":[{"name":"Department of Internal Medicine Seoul National University College of Medicine  Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Seoul National University College of Medicine  Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Won","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Seoul National University College of Medicine  Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Hyun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Seoul National University College of Medicine  Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Young","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Seoul National University College of Medicine  Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Jong","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Seoul National University College of Medicine  Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeong Wook","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Seoul National University College of Medicine  Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Bong","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Seoul National University College of Medicine  Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,2,22]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-009-0019-z"},{"key":"e_1_2_7_3_1","first-page":"59","article-title":"The role of urate and xanthine oxidase inhibitors in cardiovascular disease","volume":"26","author":"George J","year":"2008","journal-title":"Cardiovasc Ther"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.58.1.6"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1001124"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/106002809302700317"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-197911000-00004"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780290111"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2007.10.028"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.08.036"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1159\/000195632"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512143332404"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-139X.2007.00270.x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90743-5"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0409500102"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.2217\/14622416.9.11.1617"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e3282f3ef9c"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(79)70031-4"},{"key":"e_1_2_7_19_1","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archinte.1974.00320210163026","article-title":"Severe allopurinol hypersensitivity: association with thiazides and prior renal compromise","volume":"134","author":"Young JL Jr","year":"1974","journal-title":"Arch Intern Med"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(93)90101-6"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2006.077180"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.58.2.259"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.331.7517.623"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp030733"},{"issue":"5","key":"e_1_2_7_25_1","article-title":"The pathogenesis of gout","volume":"75","author":"Schumacher HR","year":"2008","journal-title":"Cleve Clin J Med"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-065X.2000.917309.x"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature01991"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.7.3905"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811053391902"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09327-3"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.20.1615"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199511163332001"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2007.11.004"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1159\/000105142"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-106005"},{"key":"e_1_2_7_36_1","first-page":"1646","article-title":"Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout","volume":"33","author":"Dalbeth N","year":"2006","journal-title":"J Rheumatol"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.60.10.981"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01580210"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2007101075"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2008010080"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270012439715","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/0091270012439715","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T12:37:31Z","timestamp":1698669451000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/0091270012439715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["10.1177\/0091270012439715"],"URL":"https:\/\/doi.org\/10.1177\/0091270012439715","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}